[Two cases of multidrug-resistant recurrent endometrial cancer successfully treated with medroxyprogesterone acetate (MPA)].
We report two cases of multidrug-resistant endometrial cancer which recurred after the initial therapy and progressed despite further anticancer chemotherapy, but could be successfully treated with medroxyprogesterone acetate (MPA). The first patient with stage IVb moderately-differentiated endometrioid adenocarcinoma of the uterine corpus underwent initial operation and postoperative chemotherapy followed by maintenance chemotherapy. Four months later, lung metastases were found. Since the hormone receptor status was positive, the patient was treated with MPA, and CR was achieved. The second patient with stage IIIc poorly-differentiated endometrioid adenocarcinoma of the uterine corpus developed lung metastases 14 months after the initial operation and postoperative chemotherapy. Subsequent chemotherapy yielded a complete response(CR). Two months later, however, a small intestinal metastasis was observed, which was treated by surgical excision and chemotherapy. The patient again remained disease-free for four months until lung metastases were observed. Since the hormone receptor status was positive, the patient was treated with MPA, and CR was achieved. No serious adverse events were observed in either patient.